Bastrop, TX, United States of America

Rafal Swiercz

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rafal Swiercz: Innovator in Modified Plasminogen Activator Inhibitor Research

Introduction

Rafal Swiercz is a notable inventor based in Bastrop, Texas, recognized for his contributions to the field of biochemistry and therapeutic development. His innovative work focuses on modified plasminogen activator inhibitor type-1 (PAI-1), which has significant implications for treating various medical conditions.

Latest Patents

Rafal Swiercz holds a patent for a discovery titled "Modified plasminogen activator inhibitor type-1 and methods based thereon." This invention is centered on the modification of PAI-1, where two or more amino acid residues lacking a sulfhydryl group are replaced with those containing a sulfhydryl group. This modification leads to the formation of intramolecular disulfide bonds, resulting in an increased in vivo half-life. The patent also encompasses modified PAI-1 proteins, derivatives, analogs, specific antibodies, nucleic acid molecules, and host cells. Furthermore, it outlines methods for producing these modified PAI-1 entities and discusses their therapeutic applications, particularly in inhibiting angiogenesis and treating diseases associated with unwanted angiogenesis and cell proliferation.

Career Highlights

Rafal Swiercz is affiliated with the Medical College of Ohio, where he has made significant strides in research and development. His work has the potential to address critical health issues, including cardiovascular diseases related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome.

Collaborations

Some of Rafal's notable coworkers include Steven H Selman and Jerzy Jankun, who have contributed to his research endeavors and the advancement of his patented technologies.

Conclusion

Rafal Swiercz's innovative research in modified plasminogen activator inhibitors represents a significant advancement in therapeutic science. His contributions have the potential to improve treatment options for various medical conditions, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…